OPKOPKO HEALTH, INC.
Pharmaceutical Preparations
- Revenue
- $607M
- 15% YoY
- Operating margin
- -19.3%
- 9.3% YoY
- EBITDA
- −$26M
- 52% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- $48M net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCClear2% of revenueOver 10% of revenue
- Payouts exceed cash flowClear-26% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear26% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $1.8B | $1.0B | $863M | $713M | $607M | 15% |
| Operating income | $19M | −$226M | −$157M | −$152M | −$117M | 23% |
| Net income | −$30.1B | −$328.4B | −$188.9B | −$53.2B | −$225.7B | 324% |
| Operating cash flow | $38M | −$95M | −$28M | −$183M | −$179M | 2.7% |
| Capex | $32M | $25M | $16M | $25M | $12M | 51% |
| Stock-based comp | $14M | $19M | $11M | $11M | $11M | 3.0% |
| Buybacks | — | $0 | $0 | $90M | $47M | 48% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $2M | $1M | 32 | 125 |
| FY2024 | $2M | $2M | 37 | 93 |
| FY2023 | $2M | $2M | 38 | 94 |
| FY2022 | $972K | −$1M | 32 | 90 |
| FY2021 | $2M | $2M | 122 | 100 |